th 2017 Why consider a tender Is it even possible What is Tendering Tendering is a process in which an entity negotiates the lowest price for a pharmaceutical drug In exchange for this low price the supplier of the drug gets their product listed on the ID: 806836
Download The PPT/PDF document "Board Discussion September 17" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Board Discussion
September 17
th
2017
Slide2Why consider a tender ?
Is it even
possible?
Slide3What is Tendering?
Tendering is a process in which
an entity,
negotiates the lowest price for a pharmaceutical
drug.
In exchange for this low price, the supplier of the drug gets their product listed on the drug plan. Often, the lowest bidder becomes the sole tender meaning their drug is the only one available in an entire class of drugs to patients.
3
Slide4Do we need a tender to achieve
better pricing?
M
arket
leader
pricing? Chapter Name
4
Slide5Do we need a tender to achieve
better pricing?
M
arket
leader
pricing? Chapter Name5
Slide6Market Losers RFVIII
Price
CSL
Novo
Pfizer
Bayer
Q4 15
.66
.79
.79
.73
Q 4 16
.66
.75
.66
.60
Q4 17
.60
.65
.66.63
6
Slide7Top 10 Questions around a Tender
10. How do we guarantee the sale?
9. How do we keep government out of process? (sort of )
8. Will Clinicians be able to agree on formulary?
7. Can we do it outside of the 340B program?
6. Will new technologies render the process obsolete before we get started?
7
Slide8Top 10 Questions around a Tender
5. Do we need a tender to accomplish the same goal?
4. How do you manage distribution?
(Wholesalers
, Specialty
Pharmacy etal
.)
3. How do we get buy-in from patient organizations/patients?
2. How do we fund the community in a tender world?
1. If we do not act will others?
8
Slide9BSI (Blood Systems Inc.) & HCWP (Hemophilia Center of Western Pennsylvania) Background
In March 2017 Blood Systems Inc. (BSI) acquired The Institute for Transfusion Medicine (
ITxM
) the parent company of the Hemophilia Center of Western Pennsylvania (HCWP). BSI is also the parent company of
BioCARE
and CanyonCARE Rx. We have been working since March to integrate operations and support services for all entities. We have identified redundancies and areas for optimization particularly between
BioCARE, CanyonCARE
and HCWP. Currently,
BioCARE
holds inventory at
ITxM
and supplies factor on consignment to all of the UPMC hospitals as well as most of the other hospitals in the Pittsburgh area.
9
Slide10BSI (Blood Systems Inc
.) & HCWP (Hemophilia Center of Western Pennsylvania) Background - Continued
All
of the thirteen (13) physicians at the
ITxM
center, including Dr Ragni, are actually UPMC employees leased to ITxM. The ITxM center currently provides many diagnostic and clinical services to the Pittsburgh area and we believe we can enhance patient care and satisfaction by adding a clinical pharmacist to our staff and expanding the services we provide.
10
Slide11Moving Forward
There are a number of synergies between the new entities of BSI and we have been developing a plan to consolidate our services. Specific to the HCWP, we have decided that
BioCARE
will provide purchasing, billing and dispensing services for the covered entity.
We
would prefer to do this through the Alliance. We believe we can do this in a very transparent way that would not interfere in any way with the strong established relationships you have with the HCWP and manufacturers.
11
Slide12The Plan
BioCARE
will hold WAC inventory at the
ITxM
center for both the hospitals and the HCWP.
When the HCWP needs product, BioCARE will sell it to them at the current 340B price or the Alliance sub-ceiling price.The clinical pharmacist at CanyonCARE
, also located at the ITxM center, will then dispense the product to the patient.
This
will allow for a true just in time inventory. The clinical staff will partner with
ITxM
diagnostic and testing staff to provide additional services to the HCWP, UPMC hospitals and local community.
12
Slide13The Plan - continued
If allowed by the Alliance,
BioCARE
would purchase all product through the Alliance contract and provide all the necessary reporting to the manufacturers.
All
volumes would still be included in the Alliance purchasing tiers and BioCARE and the HCWP would continue to participate with the Alliance in any strategic late quarter purchases to meet volume commitments or improve pricing.
13